Sign up to save your podcasts
Or
Share ONCOLOGY: New Drug RAD001 Plus Letrozole In Neoadjuvant Therapy For Breast Cancer
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
ONCOLOGY: New Drug RAD001 Plus Letrozole In Neoadjuvant Therapy For Breast Cancer
Audio Journal of Oncology, December 15th, 2007
Reporting from: San Antonio Breast Cancer Symposium, 13-16 December, 2007
New Drug RAD001 Plus Letrozole In Neoadjuvant Therapy For Breast Cancer
JOSE BASELGA, Vall d’Hebron Hospital, Barcelona
REFERENCE: ABSTRACT 2066
RAD001, a drug targeted at the mTor pathway, has been combined with letrozole in a randomised phase II trial in breast cancer. The investigators saw more responses in the experimental arm, and so Derek Thorne got the details from Jose Baselga of Vall d’Hebron Hospital in Barcelona.
View all episodes
By Audio MedicaAudio Journal of Oncology, December 15th, 2007
Reporting from: San Antonio Breast Cancer Symposium, 13-16 December, 2007
New Drug RAD001 Plus Letrozole In Neoadjuvant Therapy For Breast Cancer
JOSE BASELGA, Vall d’Hebron Hospital, Barcelona
REFERENCE: ABSTRACT 2066
RAD001, a drug targeted at the mTor pathway, has been combined with letrozole in a randomised phase II trial in breast cancer. The investigators saw more responses in the experimental arm, and so Derek Thorne got the details from Jose Baselga of Vall d’Hebron Hospital in Barcelona.